The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Author:

Evans Christopher P.,Higano Celestia S.,Keane Thomas,Andriole Gerald,Saad Fred,Iversen Peter,Miller Kurt,Kim Choung-Soo,Kimura Go,Armstrong Andrew J.,Sternberg Cora N.,Loriot Yohann,de Bono Johann,Noonberg Sarah B.,Mansbach Hank,Bhattacharya Suman,Perabo Frank,Beer Tomasz M.,Tombal Bertrand

Publisher

Elsevier BV

Subject

Urology

Reference17 articles.

1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. GLOBOCAN Web site. http://globocan.iarc.fr.

2. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Web site. http://seer.cancer.gov.

3. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006;Sathiakumar;Prostate Cancer Prostatic Dis,2011

4. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases;Zustovich;Crit Rev Oncol Hematol,2014

5. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3